Affiliation:
1. Univ. Lille, CNRS, IESEG School of Management, UMR 9221 – LEM ‐ Lille Économie Management Lille France
Abstract
AbstractI analyze how genetic testing modifies prevention actions that reduce the health and financial consequences of disease. Specifically, I determine whether individuals adjust their prevention behaviour according to the available genetic information when insurers are allowed to use test results for rate‐making purposes (laissez‐faire) and when they are not (information ban). I show that individuals exploit genetic information in the laissez‐faire regime. In the information ban regime, they do so when separating equilibria prevail, but not in case of a pooling equilibrium. None of these equilibria, however, leads to the maximization of the social welfare function. I, therefore, discuss for each potential scenario the instruments likely to restore optimality.
Reference48 articles.
1. Genetic testing with primary prevention and moral hazard;Bardey D.;Journal of Health Economics,2013
2. Welfare impacts of genetic testing in health insurance markets: will cross‐subsidies survive?;Bardey D.;Toulouse School of Economics working paper,2019
3. How is the trade‐off between adverse selection and discrimination risk affected by genetic testing? Theory and experiment;Bardey D.;Journal of Health Economics,2019
4. Genetic information: Comparing alternative regulatory approaches when prevention matters;Barigozzi F.;Journal of Public Economic Theory,2011
5. Evidence of adverse selection in the individual health insurance market;Browne M.;Journal of Risk and Insurance,1992